VINEETLAB · Vineet Laboratories Ltd · Biotechnology & Drugs
VINEETLAB · Vineet Laboratories Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
14.8% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹19 Cr
Revenue YoY
PAT YoY
+106.9%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1.5
P/S (TTM)
1.2
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| VINEETLAB (this stock) | 37.5 | 1.5 | +1.9% | +2.4% | 0.99 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 2q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-10-16 | VINEETLAB | 0 | 0 | STRONG | BULK |
| 2026-09-29 | VINEETLAB | 800000 | 1 | STRONG | BULK |
| 2026-09-01 | VINEETLAB | 100000 | 1 | STRONG | BULK |
| 2026-08-21 | VINEETLAB | 109870 | 1 | MEDIUM | BULK |
| 2026-04-24 | VINEETLAB | 0 | 0 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedVineet Laboratories Limited reported a turnover of Rs. 19117.23 Lakhs in FY 2021-2022, down from Rs.24347.89 Lakhs in FY 2020-2021, but achieved a profit after tax of Rs660.31 Lakhs, up from Rs.200.63 Lakhs. The company has no material changes affecting its financial position, no defaults in loan repayments, and no pending insolvency proceedings. It has complied with regulatory requirements, including the Prevention of Sexual Harassment Act and Insider Trading policies. The audit report noted a liability of Rs.88,60,129 due to incorrect input tax credit claims, which reduced the company's profit.
- Turnover decreased to Rs. 19117.23 Lakhs in FY2021-22, but profit after tax increased to Rs660.31 Lakhs.
- No material changes or defaults in financial position, and no pending insolvency proceedings.
- Compliance with regulatory requirements including sexual harassment prevention and insider trading policies.
- Audit report noted a liability of Rs.88,60,129 due to incorrect input tax credit claims.
Key takeaway: Vineet Laboratories Limited saw a decline in turnover but an increase in profit after tax, with no major financial defaults or regulatory issues, though it faces a liability from incorrect tax credit claims.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item); Default / Covenant Breach (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceEarlier (1-3 years ago)
The company was fined Rs.2,360 by BSE on June 30, 2022 for late submission of the Annual Secretarial Compliance Report by one day as required under Regulation 24A of SEBI LODR Regulations.
Default / Covenant Breach
2 occurrencesEarlier (1-3 years ago)
The company has not paid the outstanding liability of TDS till now.
The company has delays in depositing undisputed statutory dues including provident fund, employees state insurance, income tax, sales tax, service tax, Goods and Services Tax, duty of customs, duty of excise, cess and other material statutory dues as applicable to the appropriate authorities.
Routine disclosures
Contingent Liability
2 occurrencesEarlier (1-3 years ago)
The company has disclosed the impact of pending litigation on its financial position in its financial statements.
The company has disclosed the impact of pending litigation on its financial position in its financial statements.
Related-Party Transaction
2 occurrencesEarlier (1-3 years ago)
The company is approving material related party transactions with Vineet Life Sciences Private Limited and Organo Metallics Private Limited.
The company's members approved related party transactions with Vineet Life Sciences Private Limited and Wohler Laboratories Private Limited, which exceeded the threshold limit requiring prior approval by an ordinary resolution.
Management & Board Governance
2 occurrencesEarlier (1-3 years ago)
Satish Pandurang Samant resigned as Executive Director and CEO effective May 29, 2024. Bhaskara Reddy Karna resigned as Chairman and Independent Director effective November 14, 2024.
Mr. Satish Pandurang Samant resigned from the office of Executive Director and Chief Executive Officer w.e.f. May 29, 2024.